Log in

Relevant bibliographies by topics / Denosumab

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Denosumab'

Author: Grafiati

Published: 4 June 2021

Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Denosumab.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Denosumab"

1

&NA;. "Denosumab." Reactions Weekly &NA;, no. 1358 (July 2011): 15. http://dx.doi.org/10.2165/00128415-201113580-00056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Tolman, Cae. "Denosumab." Australian Prescriber 34 (June 1, 2011): 63–66. http://dx.doi.org/10.18773/austprescr.2011.037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Denosumab." Reactions Weekly &NA;, no. 1415 (August 2012): 19. http://dx.doi.org/10.2165/00128415-201214150-00067.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

&NA;. "Denosumab." Reactions Weekly &NA;, no. 1416 (August 2012): 20. http://dx.doi.org/10.2165/00128415-201214160-00064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

TIKOO, DEEPIKA, and GUPTA MEENAKSHI. "DENOSUMAB:." Professional Medical Journal 19, no. 02 (February 22, 2012): 141–44. http://dx.doi.org/10.29309/tpmj/2012.19.02.2027.

Full text

Abstract:

Osteoporosis is the most common metabolic bone disease in developed countries. One of its major problems is the long termmorbidity and poor quality of life of patients. Receptor activator of nuclear factor-kB, its ligand and osteoprotegrin pathway plays an importantrole in bone remodeling. Receptor activator of nuclear factor-kB interacts with receptor activator of nuclear factor-kB ligand leading to activationof osteoclasts. Denosumab, a fully monoclonal antibody to receptor activator of nuclear factor-kB ligand prevents its binding to receptoractivator of nuclear factor-kB and can effectively suppress the bone loss in osteoporosis. Various clinical studies have shown that Denosumabhas good efficacy in decreasing bone resorption and has a favourable safety profile also.

APA, Harvard, Vancouver, ISO, and other styles

6

Moen, Marit D., and Susan J. Keam. "Denosumab." Drugs & Aging 28, no. 1 (January 2011): 63–82. http://dx.doi.org/10.2165/11203300-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Muir, Victoria J., and Lesley J. Scott. "Denosumab." BioDrugs 24, no. 6 (December 2010): 379–86. http://dx.doi.org/10.2165/11203310-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Scott, Lesley J., and Victoria J. Muir. "Denosumab." Drugs 71, no. 8 (May 2011): 1059–69. http://dx.doi.org/10.2165/11207370-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Dubois, Eline A., Robert Rissmann, and Adam F. Cohen. "Denosumab." British Journal of Clinical Pharmacology 71, no. 6 (May 12, 2011): 804–6. http://dx.doi.org/10.1111/j.1365-2125.2011.03969.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

&NA;. "Denosumab." Reactions Weekly &NA;, no. 1306 (June 2010): 19. http://dx.doi.org/10.2165/00128415-201013060-00062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Denosumab"

1

Cruz, Patrícia Isabel Nunes. "" Papel do Denosumab no Tratamento da Doença Óssea Metastática"." Master's thesis, Instituto de Ciências Biomédicas Abel Salazar, 2010. http://hdl.handle.net/10216/57193.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Cruz, Patrícia Isabel Nunes. "" Papel do Denosumab no Tratamento da Doença Óssea Metastática"." Dissertação, Instituto de Ciências Biomédicas Abel Salazar, 2010. http://hdl.handle.net/10216/57193.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Tartaroti, Natalia Caroline Aguiar. "Efeito de diferentes concentrações do Denosumab sobre a viabilidade, proliferação e migração de fibroblastos em cultura." Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/23/23149/tde-12062017-164715/.

Full text

Abstract:

Atualmente é crescente o número de pacientes utilizando drogas que visam a alteração da remodelação óssea. Doenças como osteoporose e tumores ósseos têm possibilidade de tratamento com a utilização dos antirreabsortivos. Entretanto tais medicamentos apresentam, entre outros, um efeito colateral muito nocivo: a osteonecrose dos maxilares (ONM), que consiste em uma lesão rara, mas grave, da mandíbula ou maxila caracterizada por necrose óssea exposta. O denosumab é uma droga antirreabsortiva que possui um mecanismo de ação diferente do encontrado nos bisfosfonatos (BFs), medicação amplamente usada e anterior ao denosumab, entretanto já mostra efeitos colaterais similares aos BFs em relação à ONM e para ambos os medicamentos a fisiopatogenia da doença ainda não está esclarecida pela literatura Este trabalho teve como objetivo avaliar o efeito de diferentes concentrações do denosumab sobre a viabilidade, proliferação e migração de fibroblastos em cultura. Foram utilizados fibroblastos de mucosa bucal humana linhagem FMM1. Após serem submetidos aos testes de citotoxicidade com concentrações do denosumab variando de 10- 3?g a 10 - 7?g os fibroblastos não apresentaram quaisquer alterações quanto aos quesitos avaliados. Foi possível concluir que o denosumab não é citotóxico para fibroblastos em cultura. ecrose dos maxilares Fibroblastos
The number of patients using drugs that target the manipulation of bone remodeling is currently increasing. Bone volume diseases such as osteoporosis and tumors have the possibility of treatment with the use of antiresorptive medications. However, these drugs, among others, may present a very harmful side effect: osteonecrosis of the jaw (ONJ), which consists of a rare but severe injury characterized by exposed bone necrosis. The denosumab is an antiresorptive drug that presents a different mechanism of action found in bisphosphonates (BPs) and shows similar side effects to BPs regarding ONJ. BPs are a class of medication widely used and prior to denosumab. In both drugs the pathophysiology of the disease it is still not clear. This study aimed to evaluate the effect of denosumab in different concentrations on the viability, proliferation and migration of fibroblasts in culture. Were used human oral mucosa fibroblasts FMM1. After being subjected to denosumab concentrations ranging from 10-3?g to 10-7?g fibroblasts did not show any changes to the variables evaluated. It was possible to concluded that denosumab is not cytotoxic to fibroblasts in culture.

APA, Harvard, Vancouver, ISO, and other styles

4

Henriquez, Monteagudo Albert. "Denosumab jämfört med alendronat vid långtidsbehandling av osteoporos hos postmenopausala kvinnor." Thesis, Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB), 2018. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-79025.

Full text

Abstract:

Bakgrund Osteoporos är den vanligaste skelettsjukdomen i Skandinavien. Ungefär varannan kvinna och var 4:e man kommer att drabbas av någon typ av fraktur under sin livstid. Med en åldrande befolkning kommer den medicinska och socioekonomiska effekten av osteoporos, särskilt postmenopausal osteoporos, att öka. Symtomen är smärta i benen men i vissa fall kan ryggkotorna pressas ihop vilket ger en måttlig ryggvärk. I Sverige inträffar årligen ca 70 000 osteoporosrelaterade frakturer. Uppskattad kostnad 3,5 miljarder kronor. Av de 70 000 frakturer årligen så är ca 17 000 höftledsfrakturer och 10 000 är kotfraktur. Läkemedel som används som förstahandsval är bisfosfonater som alendronat i behandling mot osteoporos. I andra hand används denosumab till patienter som inte tål bisfosfonater. Syfte Syftet med studien var att jämföra effekten av alendronat och denosumab för att förebygga frakturer, samt att undersöka effekter på bentäthet (bone mineral density, BMD) av långtidsbehandling och korttidsbehandling av benskörhet/osteoporos hos postmenopausala kvinnor. Resultat Vid användning av alendronat under de första 3 åren jämfört med denosumab visar det sig att tillväxten på BMD i ländryggen är nästan densamma. Alendronat gav en ökning av BMD på 8,8% efter tre år i ländryggen och denosumab gav en BMD-ökning på 9,2% i ländryggen. Dock efter tre till fem års användning av alendronat börjar det att tappa sin effekt på ökning av BMD. Under de första tre årens använding av alendronat var NNT (numbers needed to treat) = 33 för förebyggande av vertebrala frakturer och för icke-vertebrala frakturer var NNT = 45. För denosumab var NNT = 20 för vertebrala frakturer och för icke-vertebrala frakturer var NNT = 50 under de första tre åren. Efter 10 års användning av alendronat ökade BMD i ländryggen 13,7%, medan för denosumab ökade BMD 18,4% efter 8 år användning. Slutsats Alendronat är ett bra val som läkemedel mot osteoporos de första tre till fem åren. Alendronat lagras i kroppen och fortsatt behandling har inte samma effekt på BMD-tillväxt som under de första åren. Däremot så är denosumab ett bättre alternativ som ger en fortsatt tillväxt av BMD under 8 års användning. Problemet är att denosumab är dyrt att ge till alla som har osteroporos. Förhoppningsvis blir biologiska läkemedel billigare i framtiden, så att fler människor kan behandlas med denosumab.
Background Osteoporosis is the most common skeletal disease in Scandinavia. About every other woman and every 4th man will suffer from some kind of fracture during their lifetime. With an aging population, the medical and socio-economic impact of osteoporosis, especially postmenopausal osteoporosis, will increase. The symptoms are pain in the legs, but in some cases the spine can be compressed, which causes a moderate backache. In Sweden, approximately 70,000 osteoporosis-related fractures occur annually. Estimated cost of SEK 3.5 billion. Of the 70,000 fractures annually, about 17,000 are hip fractures and 10,000 are vertebral fractures. Medicinal products used as first choice are bisphosphonates like alendronate in treatment for osteoporosis. Denosumab is used in patients who cannot take bisphosphonates. Aim The aim of the study was to compare the efficacies of alendronate and denosumab in preventing fractures and to examine the effects of long-term and short-term treatment of osteoporosis on bone mineral density (BMD) in post-menopausal women. Results When alendronate is used in the first 3 years compared with denosumab, BMD growth at the lumbar spine is almost the same. Alendronate gave a BMD increase of 8.8% after three years at the lumbar spine and denosumab a BMD increase of 9.2% at the lumbar spine. However, after three to five years of using alendronate, it begins to lose its effect on increasing BMD. In the first three years, the use of alendronate for preventing vertebral fractures gave a NNT (numbers needed to treat) = 33 and for nonvertebral fractures NNT = 45. For denosumab NNT = 20 for vertebral fractures and for nonvertebral fractures NNT = 50 in the first three years. After 10 years of use of alendronate, BMD increase at the lumbar spine was 13.7%, while denosumab resulted in a BMD growth of 18.4% after 8 years of use. Conclusion Alendronate is a good choice as a drug for the first three to five years. Alendronate is stored in the body and continued treatment does not have the same effect as the first few years. On the other hand, denosumab is a better alternative, as it results in continued BMD growth for up to 8 years of use. The problem is that denosumab is too expensive to give to everyone who has osteoporosis. Hopefully, in the future, biological medicines will become cheaper, so that more people can be treated with denosumab.

APA, Harvard, Vancouver, ISO, and other styles

5

Krumholz, Sophie Undine [Verfasser]. "Histologische und immunhistochemische Untersuchungen an Kieferosteonekrosen unter Denosumab-Therapie / Sophie Undine Krumholz." Bonn : Universitäts- und Landesbibliothek Bonn, 2019. http://d-nb.info/1200099621/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Krumholz, Sophie [Verfasser]. "Histologische und immunhistochemische Untersuchungen an Kieferosteonekrosen unter Denosumab-Therapie / Sophie Undine Krumholz." Bonn : Universitäts- und Landesbibliothek Bonn, 2019. http://d-nb.info/1200099621/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Heydasch, Madlen [Verfasser], and Sven [Akademischer Betreuer] Otto. "Denosumab-assoziierte Kiefernekrosen : klinische Präsentation und potenzielle Risikofaktoren / Madlen Heydasch ; Betreuer: Sven Otto." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2019. http://d-nb.info/120306702X/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Poubel, Victor Lousan do Nascimento. "Efeito dos fármacos antirreabsortivos, zoledronato e denosumab, no metabolismo ósseo mandibular de ratos." reponame:Repositório Institucional da UFSC, 2016. https://repositorio.ufsc.br/xmlui/handle/123456789/167816.

Full text

Abstract:

Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-Graduação em Odontologia, Florianópolis, 2016
Made available in DSpace on 2016-09-20T04:23:17Z (GMT). No. of bitstreams: 0 Previous issue date: 2016Bitstream added on 2016-09-27T04:02:31Z : No. of bitstreams: 1 340520.pdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)
A osteonecrose medicamentosa dos maxilares (OMM) local é um efeito adverso do uso contínuo de drogas antirreabsortivas. A OMM está associada a procedimentos odontológicos, como extrações dentárias. O presente trabalho teve o objetivo de analisar a influência de dois fármacos supressores do metabolismo ósseo, Zoledronato (ZOL) e Denosumab (DNB), no reparo ósseo mandibular de roedores submetidos a extração dentária.. Foram utilizados 33 ratos Wistar, machos de 120 dias divididos em três grupos: controle (n=11), ZOL (n=11) e DNB (n=11), os quais foram submetidos a duas aplicações semanais na dosagem de 0,1 mg/kg, 0,125 mg/kg e 0,250 mg/kg, via de administração intraperitoneal, respectivamente. O término das infusões medicamentosas foi após 4 semanas. Após uma semana do início da pesquisa, os animais foram submetidos à extração dentária do primeiro molar esquerdo. Após 28 dias os animais foram sacrificados. As peças foram fotografadas, tomografadas e, posteriormente, processadas para análise histológica e imunoistoquímica, a fim de verificar a expressão do ligante do receptor ativador nuclear kB (RANKL) e da osteoprotegerina (OPG). Os resultados demonstraram que o grupo ZOL foi superior na reparação alveolar em comparação somente com o DNB na análise tomográfica, p<0,05. Nas demais análises executadas, não foi possível observar diferença estatisticamente significativa entre os grupos. Na posologia utilizada na pesquisa foi possível constatar que o ZOL teve resultados que demonstram sua influência no metabolismo ósseo de forma mais intensa.

Abstract : Medication-Related Osteonecrosis of the Jaw (MRONJ) is an adverse effect that comes from continuous administration of antirresorptive drugs associated with local injury, such as teeth extraction. The aim of this study was to analyze the effect of two drugs which supress bone metabolism, Zoledronate (ZOL) and Denosumab (DNB). It was chosen 33 male Rat Wistar, with 120 days of age. They were splitted in three groups: control (n=11), ZOL (n=11) and DNB (n=11), and were submitted to two doses weekly with 0,1 mg/kg, 0,125 mg/kg and 0,250 mg/kg for control, ZOL and DNB, respectivally. The end of the drug infusion was 4 weeks after the beginning of the treatment. After one week of starting the medications protocols, the first left molar was extracted. Twenty eight days after the start point, the animals were sacrificed. The jaws were removed and photographed. After the pieces were subjected to tomographic analysis and processed for histological and imunohistochemistry analysis , using the receptor activator nuclear kB ligant (RANKL) and osteoprotegerin (OPG) markers. The results showed that ZOL group had a better alveolar bone healing on tomographic analysis, p<0,05. In other analyzes there was no difference between groups. The doses used in this research were able to conclude that ZOL had effects more prominent that demonstrate the in influence of this drug on bone metabolism.

APA, Harvard, Vancouver, ISO, and other styles

9

Kaboudian, Tina Tisa. "Effekterna av alendronat, denosumab och teriparatid på frakturrisk och bentäthet hos postmenopausala kvinnor med osteoporos." Thesis, Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB), 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-44890.

Full text

Abstract:

Background Osteoporosis is a disease with reduced bone mass and deterioration of bone structure, which leads to increased risk of fractures (1.9). Approximately one in four men and one in two women will at some time in life suffer a fracture due to osteoporosis. Supplemental calcium and vitamin D have long been a cornerstone of osteoporosis treatment. Drugs that are also used clinically for the treatment of osteoporosis include bisphosphonates, denosumab, selective estrogen receptor modulators (SERM), and strontium (3). Bisphosphonates are the most used osteoporosis drugs (4). The bisphosphonates alendronate, risedronate and zoledronic acid are interchangeable as first choice treatment of osteoporosis in postmenopausal women. Denosumab is another drug with antiresorptive effects that has been registered for the treatment of postmenopausal osteoporosis in recent years. Teriparatide (PTH) is an anabolic drug used for osteoporosis (3.6). Objective: The objective of this study was to examine the efficacy of alendronate, denosumab and teriparatide on fracture risk and bone mineral density in postmenopausal women with osteoporosis with the help of published meta-analyses and clinical trials. Result: Examined articles showed that alendronate treatment for at least one year reduces the risk of vertebral fractures with NNT = 17-50 and the risk of non-vertebral fractures with NNT = 50. PTH reduced the risk of vertebral fractures with NNT = 9.8 and non-vertebral fractures with NNT = 29. A statistically significant increase in BMD was also observed with an increase in BMD of 8.14% in the spine and 2.48% in the hip. PTH treatment compared with alendronate treatment was found to have a statistically significant difference (P=0.004) in the reduction of non-vertebral fracture risk with NNT = 10,4. Teriparatid treatment also showed more positive effects as compared to alendronate on BMD increases. Denosumab treatment for 36 months reduced the risk of fractures with a relative reduction of 68% for vertebral fractures and a relative reduction of 20% for non-vertebral fractures. Denosumab treatment for 12 months compared with alendronate therapy in postmeopausala women showed no statistically significant difference in fracture risk (p=0,19). The increase in BMD was, however, greater in the denosumab group than in the alendronate group, with 0.53% in the distal radius, 1.14% in the hip , 0.77% in the lumbar spine and 0.79% in the femoral neck. Conclusion: These studies show that all three drugs, alendronate, PTH and denosumab, have good effects on reducing the risk of fractures in postmenopausal women. All drugs lead to increases in BMD in different parts of the skeleton. Reduction of fracture risk was greater for both denosumab treatment and PTH treatment compared to alendronate treatment, also BMD increased more with denosumab or PTH treatment compared with alendronate treatment.
Bakgrund Osteoporos är ett sjukdomstillstånd med reducerad benmassan och försämringar i benvävnadens struktur, som leder till att man lättare kan få benbrott. Ungefär var fjärde man och varannan kvinna drabbas någon gång i livet av en fraktur på grund av osteoporos. Tillägg av kalcium och vitamin D har länge varit en grundval inom osteoporosbehandlingen. Läkemedel som också används kliniskt för osteoporosbehandling inkluderar bisfosfonater, denosumab, selektiva östrogenreceptormodulatorer (SERM), samt strontiumsalt. Bisfosfonater är den mest använda gruppen av osteoporosläkemedel. Bisfosfonater som alendronate, risedronat och zoledronsyra vilka är utbytbara mot varandra räknas som förstahandsval i behandling av osteoporos hos postmenopausala kvinnor. Denosumab är ett annat osteoporosläkemedel med antiresorptiv effekt som registrerats för behandling av postmenopausal osteoporos de senaste åren. Teriparatid (PTH) är ett anabolt läkemedel som också används mot osteoporos. Syftet: Syftet med detta arbete var att med hjälp av publicerade meta-analyser och kliniska studier undersöka effekterna av alendronat, denosumab och teriparatid på frakturrisk och bentäthet hos postmenopausala kvinnor med osteoporos. Resultat: Granskade artiklar på postmenopausala kvinnor visar att alendronatbehandling under minst ett år minskar risken för vertebrala frakturer med NNT =17-50 och för icke-vertebrala frakturer med NNT=50. PTH minskade risken för vertebrala frakturer med NNT=9,8 och icke-vertebrala frakturer med NNT= 29. Statistiskt signifikant ökning i BMD förelåg också med 8.14% i ryggrad och 2,48% i höften. PTH behandling jämfört med alendronat visade en statistiskt signifikant skillnad (p=0.004) för minskning av icke-vertebrala frakturer med NNT=10,4. Teriparatidbehandling visade också mer positiva effekter jämfört med alendronat avseende ökningar i BMD. Denosumabbehandling i 36 månader minskade risken för frakturer med en relativ minskning på 68 % för vertebrala frakturer och en relativ minskning på 20% för icke-vertebrala frakturer. Denosumabbehandling under 12 månader jämfört med alendronatbehandling hos postmenopausala kvinnor gav ingen statistiskt signifikant skillnad (p =0.19) i frakturrisk. Ökning av BMD var dock större i denosumabgruppen än i alendronatgruppen, 0.53% i distala radius, 1.14 % i höften, 0.77% i ländryggen och 0.79% i lårbenhalsen. Slutsats: Studierna visade att alla tre undersökta läkemedel, alendronat, PTH och denosumab, har goda effekter på minskning av frakturrisk hos postmenopausala kvinnor. Samtliga läkemedel leder till ökning av BMD i olika delar av skelettet. Minskningen av frakturrisk var större för både denosumabbehandling och PTH-behandling jämfört med alendronat, även BMD ökade mer vid denosumab- eller PTH-behandling jämfört med alendronatbehandling.

APA, Harvard, Vancouver, ISO, and other styles

10

Mosch, Alexander [Verfasser], and Christoph [Akademischer Betreuer] Klingelhöffer. "Physiologische Konzentrationen Denosumab steigern die osteogene Differenzierung von humanen mesenchymalen Stammzellen / Alexander Mosch ; Betreuer: Christoph Klingelhöffer." Regensburg : Universitätsbibliothek Regensburg, 2019. http://d-nb.info/1197901213/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Denosumab"

1

Otto, Sven. Medication-Related Osteonecrosis of the Jaws: Bisphosphonates, Denosumab, and New Agents. Springer, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Otto, Sven, and Sven Ed Otto. Medication-Related Osteonecrosis of the Jaws: Bisphosphonates, Denosumab, and New Agents. Springer Berlin / Heidelberg, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Otto, Sven. Medication-Related Osteonecrosis of the Jaws: Bisphosphonates and Denosumab, and New Agents. Springer, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Elder, Grahame J. Metabolic bone disease after renal transplantation. Edited by Jeremy R. Chapman. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0288.

Full text

Abstract:

Patients who undergo kidney transplantation have laboratory, bone, and soft tissue abnormalities that characterize chronic kidney disease mineral and bone disorder (CKD-MBD). After successful transplantation, abnormal values of parathyroid hormone, fibroblast growth factor 23, calcium, phosphate, vitamin D sterols, and sex hormones generally improve, but abnormalities often persist. Cardiovascular risk remains high and is influenced by prevalent vascular calcification, and fracture risk increases due to a combination of abnormal bone ‘quality’, compounded by immunosuppressive drugs and reductions in bone mineral density. Patients with well managed CKD-MBD before transplantation generally have a smoother post-transplant course, and it is useful to assess patients soon after transplantation for risk factors relevant to the general population and to patients with CKD. Targeted laboratory assessment, bone densitometry, and X-ray of the spine are useful for guiding therapy to minimize post-transplant effects of CKD-MBD. To reduce fracture risk, general measures include glucocorticoid dose minimization, attaining adequate 25(OH)D levels, and maintaining calcium and phosphate values in the normal range. Calcitriol or its analogues and antiresorptive agents such as bisphosphonates may protect bone from glucocorticoid effects and ongoing hyperparathyroidism, but the efficacy of these therapies to reduce fractures is unproven. Alternate therapies with fewer data include denosumab, strontium ranelate, teriparatide, oestrogen or testosterone hormone replacement therapy, tibolone, selective oestrogen receptor modulators, and cinacalcet. Parathyroidectomy may be necessary, but is generally avoided within the first post-transplant year. A schema is presented in this chapter that aims to minimize harm when allocating therapy.

APA, Harvard, Vancouver, ISO, and other styles

5

Hutchison, Alastair J., and Michael L. Picton. Fractures in patients with chronic kidney disease. Edited by David J. Goldsmith. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0121.

Full text

Abstract:

Patients with any degree of chronic kidney disease (CKD) have a much higher risk of fractures than the general population, and the risk of death at 1 year post hip fracture in a dialysis patient is over 60%, compared to less than 20% for a non-CKD patient. The assessment of fracture risk and diagnosis of the underlying skeletal pathology in CKD patients is a significant clinical challenge. Non-invasive imaging techniques are not totally reliable in the general population, and the presence of advanced CKD (stages 4, 5, and 5D) renders them largely useless. Bone strength is not determined only by quantity of bone, and renal osteodystrophy can significantly affect bone quality, rendering it liable to fracture even in the presence of a normal bone density measurement. Currently, the only reliable method of assessing both quantity and quality of bone is the examination of trans-iliac bone biopsy, which is generally, but probably incorrectly, perceived to be overly invasive. However, identifying the cause of reduced bone strength and fractures may influence the choice of therapy. For example, in the presence of low-turnover states such as adynamic bone, antiresorptive agents may be ineffective. Pharmaceuticals licensed for the treatment of osteoporosis in the general population can be used similarly in patients with CKD 1–3 without dosage alteration. In CKD 4, post-hoc analyses suggest denosumab is effective and safe, based on a 3-year study that included 73 such patients. In CKD 5 and 5D no dependable data exists to guide therapy, and it should probably be reserved for patients who have already suffered and survived a fracture, and are therefore at high risk of death from a second event.

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Denosumab"

1

McClung, Michael R. "Denosumab." In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 420–27. Ames, USA: John Wiley & Sons, Inc., 2013. http://dx.doi.org/10.1002/9781118453926.ch50.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Bolognese, Michael A. "Denosumab." In Osteoporosis, 144–57. Chichester, UK: John Wiley & Sons, Ltd, 2013. http://dx.doi.org/10.1002/9781118316290.ch10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Tridente, Giuseppe. "Denosumab." In Adverse Events with Biomedicines, 183–92. Milano: Springer Milan, 2013. http://dx.doi.org/10.1007/978-88-470-5313-7_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Meyer, Torsten. "Denosumab (Prolia®)." In Handbook of Therapeutic Antibodies, 1521–30. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2014. http://dx.doi.org/10.1002/9783527682423.ch53.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bartl, Reiner. "Bisphosphonate und Denosumab." In Osteoporose in der Praxis, 117–30. Berlin, Heidelberg: Springer Berlin Heidelberg, 2022. http://dx.doi.org/10.1007/978-3-662-64207-8_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bartl, Reiner. "Bisphosphonate und Denosumab." In essentials, 31–44. Berlin, Heidelberg: Springer Berlin Heidelberg, 2022. http://dx.doi.org/10.1007/978-3-662-65475-0_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bartl, Reiner, and Christoph Bartl. "Bisphosphonate und Denosumab." In Das Osteoporose Manual, 205–23. Berlin, Heidelberg: Springer Berlin Heidelberg, 2021. http://dx.doi.org/10.1007/978-3-662-62528-6_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Samuels, Blossom, Yi Liu, and Joseph Lane. "Role of bisphosphonates and denosumab." In Surgical and Medical Treatment of Osteoporosis, 59–67. Boca Raton : CRC Press, [2020]: CRC Press, 2020. http://dx.doi.org/10.1201/9780429161087-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Then, Cornelia, Emmo von Tresckow, Reiner Bartl, and Fuat S. Oduncu. "Bisphosphonate and Denosumab Therapy: Fields of Application." In Medication-Related Osteonecrosis of the Jaws, 17–26. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43733-9_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Bartl, Reiner, and Emmo von Tresckow. "Pharmacological Aspects of Antiresorptive Drugs: Bisphosphonates and Denosumab." In Medication-Related Osteonecrosis of the Jaws, 1–15. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43733-9_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Denosumab"

1

Scheiner, Stefan, Peter Pivonka, David W. Smith, and Colin R. Dunstan. "Computer Simulation-Based Modeling of the Pharmaceutical Intervention of Postmenopausal Osteoporosis by Denosumab." In ASME 2012 11th Biennial Conference on Engineering Systems Design and Analysis. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/esda2012-82990.

Full text

Abstract:

Postmenopausal osteoporosis (PMO), leading to a higher bone fracture risk, is characterized by a significantly increasing bone porosity. Recently, denosumab, which is able to efficiently interfere with bone resorption, has been approved for the treatment of PMO. In order to optimize the design of drug administration regimes, we propose a computational methodology, based on mechanistic mathematical modeling of bone remodeling, considering the governing biochemical and biomechanical regulation mechanisms, and the targeted action of denosumab. The time-dependent serum concentration of denosumab, obtained from a pharmacokinetics model, is fed into a bone cell population model, allowing for prediction of porosity evolution in PMO patients. In order to account for the mechanobiology of bone remodeling, we utilize the concept of continuum micromechanics, which accurately provides the actual (microscopic) strain state of the investigated bone. Finally, different drug administration regimes are simulated, and their effect on the bone microarchitecture is discussed.

APA, Harvard, Vancouver, ISO, and other styles

2

Potier, J., S. Grenier, C. Cervellera, and B. Lefevre. "Osteonecrose mandibulaire sous denosumab et anastrozole." In 63ème Congrès de la SFCO, edited by S. Boisramé, S. Cousty, J. C. Deschaumes, V. Descroix, L. Devoize, P. Lesclous, C. Mauprivez, and T. Fortin. Les Ulis, France: EDP Sciences, 2015. http://dx.doi.org/10.1051/sfco/20156303012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Morena, Isabel de la, Sara Vela, Juan Alberto Paz Solarte, Diego Bedoya, and M. Jose Galindo. "AB0827 IS DENOSUMAB SAFE IN HIV PATIENTS?" In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7858.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Urionaguena, Irati, P. Sandra, Chinchilla Gallo, Sandra Hernandez Gomez, Jose Francisco Garcia Llorente, Izaskun Aizpurua Manso, and Nuria Vegas Revenga. "AB0857 DENSITOMETRY VALUES CHANGE WHEN STOPPING DENOSUMAB." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.4338.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Sanguesa, Clara, Susana Holgado Pérez, Melania Martínez-Morillo, Jordi Camins-Fàbregas, Ivette Casafont-Solé, Annika Nack, águeda Prior-Español, et al. "AB0852 DOES INADEQUATE RESPONSE TO DENOSUMAB TREATMENT EXIST?" In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7913.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Al-Saleh, J., N. Salah, AS Hasan, S. Mohamad, FA ElBadawi, and M. Khamashta. "AB0839 The efficacy and safety of denosumab local experience)." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.6791.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Yoshii, I. "AB0443 The effects of denosumab for rheumatoid arthritis patient." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.1903.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

VIERHOUT, CLAUDIA VALERIA, NADIA REGINA BOSSOLAN SCHINCARIOL, JOSÉ ALEXANDRE MENDONÇA, LUCAS EDUARDO PEDRI, ANDRE MARUN LYRIO, RUBENS BONFIGLIOLI, JOSÉ ROBERTO PROVENZA, et al. "MULTIPLE VERTEBRAL FRACTURES SECONDARY TO IRREGULAR USE OF DENOSUMAB." In 36º Congresso Brasileiro de Reumatologia. São Paulo: Editora Blucher, 2019. http://dx.doi.org/10.5151/sbr2019-181.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Salom, C., F. Bejarano, C. Campabadal, S. Conde, L. Castillo, N. Marco, A. Sanjuan, I. Sacanella, H. Suñer, and L. Canadell. "4CPS-134 Optimisation of denosumab prescription in osteoporosis patients." In 26th EAHP Congress, Hospital pharmacists – changing roles in a changing world, 23–25 March 2022. British Medical Journal Publishing Group, 2022. http://dx.doi.org/10.1136/ejhpharm-2022-eahp.155.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Naudy, Cristian, Homero Sariego, Katherine Walker, Joaquin Vallejos, and Matias Gomez. "Treatment with Denosumab in Clival Giant Cell Tumor: Imaging Finding." In 29th Annual Meeting North American Skull Base Society. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1679737.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Denosumab"

1

Sun, Yang, and Yue Li. Efficacy of the combination of teriparatide and denosumab in the treatment of postmenopausal osteoporosis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2022. http://dx.doi.org/10.37766/inplasy2022.1.0092.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!